What are the indications and contraindications of icorelatumumab?

Epcoritumab (Epcoritamab) is a bispecific antibody that can simultaneously bind and guide CD20-positive B cells and CD3-positive T cells, activating T cells’ immune attack on B cells. As a new type of immunotherapy drug, icorelatumumab is mainly used to treat relapsed or refractory hematological malignancies, especially for patient groups who still need new treatment options after failure of multiple lines of treatment.

The main indications include diffuse largeB-cell lymphoma (DLBCL; non-Hodgkin lymphoma) and high-gradeB-cell lymphoma. DLBCL is the most common type of non-Hodgkin lymphoma, which often progresses rapidly and is difficult to treat. Ikorituzumab is indicated for patients who have not responded to conventional treatments, especially relapsed or refractory patients who have received at least two lines of systemic therapy. In addition, high-grade B-cell lymphoma is also a type of cancer that progresses quickly and is difficult to treat. Icoritumab can provide new treatment options for these patients.

Another important indication is follicular lymphoma (FL). Follicular lymphoma is a chronic and potentially relapsing type of lymphoma. Ikorituzumab is suitable for patients who still experience disease progression or recurrence after receiving two or more lines of treatment, especially for cases with poor efficacy, and can provide new treatment hope.

However, while icarituzumab has significant therapeutic effects and provides a new option for patients who have failed treatment, it is not suitable for all patients. For example, use needs to be avoided in patients with a history of severe allergic reactions or allergies to the components of icarelatumumab. In addition, because immunotherapy may trigger excessive activation of the immune system, there is a risk of immune-mediated side effects, such as cytokine release syndrome (CRS), neurotoxicity, etc., which may seriously affect the therapeutic effect in some patients.

Reference materials:https://www.drugs.com/epcoritamab.html